Abstract
Treatable Traits have been proposed as a new paradigm for the management of airway diseases, particularly complex disease, that aims to apply personalised medicine to each individual to improve outcomes. Moving new treatment approaches from concepts to practice is challenging, but necessary. In an effort to accelerate progress in research and practice relating to the Treatable Traits approach, an International Research Workshop – Treatable Traits Down Under, was convened in Melbourne, Australia in May 2018. In this article we report the key concepts and research questions that emerged in discussions during the meeting. We propose a programme of research that involves gaining international consensus on candidate traits, recognising the prevalence of traits and identifying a potential hierarchy of traits based on their clinical impact and responsiveness to treatment. We also reflect on research methods and designs that can generate new knowledge related to efficacy of the Treatable Traits approach and consider multidisciplinary models of care that may aid its implementation into practice.
Footnotes
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.
Conflict of interest: Dr. McDonald reports grants from GSK, during the conduct of the study; grants and personal fees from GSK, grants and personal fees from AstraZeneca, personal fees from Menarini, grants from Cyclopharm LTD, outside the submitted work.
Conflict of interest: Dr. Fingleton reports non-financial support from GlaxoSmithKline, during the conduct of the study; personal fees from AstraZeneca Ltd, personal fees and non-financial support from Boerhinger-Ingleheim, grants from GlaxoSmithKline, grants from Fisher & Paykel Ltd., New Zealand, outside the submitted work.
Conflict of interest: Dr. Agusti reports grants and personal fees from AstraZeneca, grants and personal fees from Menarini, personal fees from Chiesi, personal fees from GSK, personal fees from Nuvaira, personal fees from Boheringer-Ingelheim, outside the submitted work.
Conflict of interest: Dr. Hiles’ salary was supported by grants from GlaxoSmithKline and AstraZeneca, paid to her institution (University of Newcastle), during the conduct of the study. Dr. Hiles reports grants from GlaxoSmithKline, grants from AstraZeneca, during the conduct of the study.
Conflict of interest: Dr. Vanessa Clark receives a fellowship from the National Health and Medical Research Council, Centre of Research Excellence in Severe Asthma.
Conflict of interest: Dr. Holland has nothing to disclose.
Conflict of interest: Dr. Marks reports grants from GSK Australia, grants from AstraZeneca (Australia), outside the submitted work.
Conflict of interest: Dr. Bardin reports personal fees from GSK, BI, AZ, during the conduct of the study.
Conflict of interest: Dr. Pavord reports personal fees from AstraZeneca, personal fees from GSK, personal fees from Boehringer Ingelheim, grants and personal fees from Chiesi, personal fees from Sanofi/Regeneron, personal fees from Circassia, personal fees from Merck, personal fees from Novartis, personal fees from Mundipharma, personal fees from Teva, personal fees from Knopp, grants and personal fees from Afferent, personal fees from Roche/Genentech, outside the submitted work.
Conflict of interest: Dr. Wark receives grants from The University of Newcastle, John Hunter Hospital Charitable Trust, grants from Hunter Medical Research Institute, grants from National Health and Medical Research Council, during the conduct of the study; Has taken part in advisory boards for Astra Zeneca, Bohringer Ingelheim, Novartis and Vertex. Personal fees from Astra Zeneca GlazoSmithKline, and Vertex outside the submitted work.
Conflict of interest: Dr. Gibson reports grants and personal fees from AstraZeneca, GlaxoSmithKline, Novartis, grants from NHMRC (Australian Govt), outside the submitted work.
Conflict of interest: Dr. Beasley reports grants from Health Research Council of New Zealand , grants and personal fees from Astra Zeneca, grants and personal fees from GlaxoSmith Kline, grants from Genentech, outside the submitted work.
This is a PDF-only article. Please click on the PDF link above to read it.
- Copyright ©ERS 2019